WuXi Chemistry

Radionuclide Drug Conjugates (RDCs) have shown great potential in early-stage tumor imaging and radiopharmaceutical therapy. In this WuXi TIDES case study, discovery how our integrated CMC services enabled a seamless transition from discovery to process development and manufacturing, across both small molecules and peptides. Our approach accelerated the development of a complex RDC candidate, achieving milligram-scale discovery synthesis in just 1 month and kilogram-scale manufacturing in only 3 months, paving the way for a successful #IND submission. Learn more: https://lnkd.in/g6AmChYd #Peptide #SmallMolecule #Radiopharmaceutical #DrugConjugates #DrugDevelopment #CRDMO

Our latest whitepaper explores advanced, data-driven approaches to benchmark and control critical impurities in nucleoside phosphoramidites—key building blocks in therapeutic oligonucleotides. By enhancing reproducibility, scalability, and regulatory compliance, WuXi TIDES produces high-quality amidites and provides comprehensive support throughout the oligonucleotide drug development process, from discovery through commercialization.   WuXi TIDES simplifies regulatory submissions for our customers by documenting select amidite products and PMO monomers in Drug Master Files (DMFs)—comprehensive FDA filings that provide detailed records of our manufacturing and quality control processes. Moreover, WuXi TIDES Catalog Products now offers over 600 amidite products, available for direct purchase online, with select amidites stocked globally in the US and Europe.   Download the whitepaper to learn more: https://lnkd.in/eyfeT4ca

WuXi TIDES Catalog Products has expanded its portfolio to now offer a nucleotide portfolio, featuring nucleoside triphosphates (NTPs) for mRNA synthesis, deoxynucleotides (dNTPs) and modified NTP products for innovative enzymatic synthesis solutions. Additionally, we offer cap precursor reagents to provide high-quality solutions for the synthesis of capping reagents.   To learn more and discover our new product offerings: https://lnkd.in/e4naERiv

This December marks WuXi AppTec’s 24th anniversary! For 24 years, our belief that “every drug can be made and every disease can be treated” has continued to inspire us as we look to the future with determination and optimism. Starting from a single laboratory, we have grown into a global enterprise with 32 R&D and manufacturing sites worldwide, dedicated to advancing breakthroughs in life-sciences. Thank you to our customers, partners, and global teams - your commitment to our mission of enabling transformative solutions has been the heartbeat of our success. Together, we’re not just imagining a healthier world - we are building it.

To meet the growing global demand for peptide therapeutics, WuXi TIDES is pleased to announce the expansion of our Solid Phase Peptide Synthesis (SPPS) capabilities with an additional 9,000 L of capacity at our Changzhou site, including reactors ranging from 500 L to 3,000 L. We now offer over 41,000 L of SPPS capacity! This expansion further enhances our integrated peptide CRDMO services, enabling us to accelerate the development of novel peptide therapeutics from discovery through clinical development and commercialization. By continuing to strengthen our platform capabilities, we aim to stay ahead of market needs and provide our partners with expertise, quality, and reliability. Stay tuned! We have more SPPS capacity expansions planned for 2025 … Learn more: https://lnkd.in/g6AmChYd

As we celebrate Thanksgiving, our global teams at WuXi STA and WuXi TIDES want to express heartfelt gratitude to our clients, partners, and colleagues who make our work possible. Thank you for your trust and support. Wishing you and your loved ones a joyful and peaceful Thanksgiving. #Thanksgiving #Gratitude #WuXiSTA #WuXiTIDES

Day 1 at BOS Manchester 2024 is underway! Visit WuXi STA and WuXi TIDES at Booth #32 to explore how our integrated CMC solutions can accelerate drug development and enhance early-stage success for your projects. Whether your project involves small molecules, oligonucleotides, peptides, or their conjugates, our comprehensive approach offers the capabilities and capacity to deliver APIs and drug products in oral and parenteral dosage forms. Discover how we can help advance your molecule from pre-clinical development through commercialization—faster, with WuXi Speed. https://lnkd.in/eTxsZr6W #BOSManchester2024 #WuXiSTA #DrugDevelopment #CMC

At WuXi STA's San Diego site, teamwork is the driving force behind our success. Keith R. Bergs, Senior Manager of Materials Management, embodies this spirit: “Teamwork is truly at the core of everything we do here. It’s about combining our strengths and supporting one another.” Since joining us in 2017, Keith has witnessed the site’s growth, evolving into a facility that supports both API and drug product development and manufacturing. “Being a part of this journey has been one of the most rewarding parts of my career,” Keith says.   Fostering collaboration across diverse talents, we thrive as one family united by a commitment to healthcare innovation for our partners. Learn more about working with us: https://lnkd.in/e2UeJY-d  

We are proud to announce that WuXi AppTec has received a gold medal in the 2024 EcoVadis Sustainability Rating, placing us in the top 2% of all participating companies! This achievement reflects our commitment to sustainability and our ongoing efforts to integrate environmental and social responsibilities throughout our operations. Looking ahead, we will continue to advance #ESG efforts, support customers in delivering innovative therapies, and create a lasting, positive impact on the healthcare industry.  Read more: https://lnkd.in/ee26vAbR

We had a great time connecting with the TIDES community last week at #TIDESEurope in Hamburg. Thank you to everyone who stopped by our booth to explore our integrated CRDMO platform for oligonucleotide and peptide-based therapeutics. This year’s event highlighted the power of collaboration and innovation driving remarkable progress in the field. At WuXi TIDES, we’re committed to providing the expertise and tailored solutions to advance your projects at every stage, from discovery to commercialization. Want to learn more about how WuXi TIDES can support your next project? Visit us here: https://lnkd.in/g6AmChYd #TIDESEurope #Oligonucleotides #Peptides #DrugDevelopment #CMC #CRDMO #WuXiTIDES